SGK1 and diffuse large B-cell lymphoma: We believe that our study makes a significant contribution to the literature and will be of interest to the readership of your journal, because it provides strong evidence that mutations in serum and glucocorticoid‐inducible kinase 1 (SGK1) are associated with better prognosis in patients with diffuse large B‐cell lymphoma and, thus, that targeting SGK1 may improve patient prognosis.